GenScript ProBio Enters into Agreement with SYNIMMUNE for Manufacturing of their Innovative Antibody Drug
NANJING, China, Sept. 6, 2021 /PRNewswire/ --GenScript ProBio is delighted to announce the signing of a manufacturing service agreement for Synimmune's innovative FLYSYN antibody project for clinical Phase II production.
- NANJING, China, Sept. 6, 2021 /PRNewswire/ --GenScript ProBio is delighted to announce the signing of a manufacturing service agreement for Synimmune's innovative FLYSYN antibody project for clinical Phase II production.
- "GenScript ProBio and SYNIMMUNE GmbH entered into collaboration on FLYSYN antibody project for technology transfer and manufacturing of drug substance and drug product for Clinical Phase II trials, it is our pleasure to support this innovative antibody project," said Dr. Brian Min, CEO of GenScript ProBio, "GenScript ProBio's GMP manufacturing center meets global regulatory requirements.
- We are confident that GenScript ProBio will produce SYNIMMUNE's lead antibody drug product FLYSYN to all global quality GMP standards within the agreed upon timeline.
- GenScript ProBio's innovative solutions for antibody drug development include antibody drug discovery, antibody engineering and antibody characterization.